Saturday 17 October 2026 Export TECH’s income statement to Excel — free account

Bio-Techne Corp

Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025. In the quarter to June 2026, revenue grew 1.33%, EPS grew 418.2%, free cash flow fell 6.83% and total debt fell 42.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years.

72.54 0.02 +0.03%

Follow TECH

Alert me

Market cap: $11.4B
P/E: 62.0×
Fwd P/E: 37.6×
Dividend yield: 0.44%
F-score: 9/9
Altman Z: 15.50
Beneish M: −2.52
Dividend safety: 78/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Insider Decisions trades per month

Total sells 0.44

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	1	—	—	1	—	—	—	—	—

Insider Ownership 0.01%

Capital & Financial Ratios $m

Market Cap 11,370.00

Revenue 1,215.04

Net Income 181.86

Free Cash Flow 263.22

Net Debt (64.71)

Current Ratio 4.55

Debt/Equity 0.09

P/E ratio 62.00

Fwd P/E 37.60

P/S ratio 9.31

P/B ratio 5.37

Past 5Y EPS Growth 5.98%

This Y EPS Growth 5.33%

Next Y EPS Growth 16.91%

Next Y revenue growth 4.36%

Next 5Y EPS Growth 7.98%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 58.50%

10-year low 10-year high

P/S against its own 10 years 43.16%

10-year low 10-year high

P/B against its own 10 years 41.25%

10-year low 10-year high

EV/Sales against its own 10 years 39.14%

10-year low 10-year high

EV/FCF against its own 10 years 38.78%

10-year low 10-year high

Dividends

Payout Ratio 0.28

Annual Dividend Rate 0.32

Annual Dividend Yield 0.44%

	total	individual payouts
2029	Powerpack
2028	Powerpack
2027	Powerpack
2026	0.32	0.08 0.08 0.08
2025	0.32	0.08 0.08 0.08 0.08
2024	0.32	0.08 0.08 0.08 0.08
2023	0.32	0.08 0.08 0.08 0.08
2022	0.64	0.08 0.08 0.08 0.08 0.32
2021	0.32	0.08 0.08 0.08 0.08
2020	0.32	0.08 0.08 0.08 0.08
2019	0.32	0.08 0.08 0.08 0.08
2018	0.32	0.08 0.08 0.08 0.08
2017	0.32	0.08 0.08 0.08 0.08
2016	0.32	0.08 0.08 0.08 0.08

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	2026
Cash	204	153	162	265
Receivables	218	241	207	217
Inventory	172	180	189	196
Other	27	43	50	67
	621	617	608	744

	2023	2024	2025	2026
Payables	26	38	25	27
ST’ Debt	—	—	—	—
Other	24	30	34	40
	129	159	176	164

Compound Annual Growth %

	10y	5y	3y
Sales	9.31%	5.47%	2.25%
Cash Flow	7.32%	(3.67%)	4.71%
Earnings	5.70%	5.31%	(13.93%)
Book Value	9.14%	6.06%	2.35%

Revenue $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	287	296	311	321	1,215
’25	289	297	316	317	1,220
’24	277	273	303	306	1,159
’23	270	272	294	301	1,137
’22	258	269	290	288	1,106
’21	204	224	244	259	931

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	28	82	87	95	292
’25	64	84	41	98	288
’24	59	83	81	75	299
’23	56	64	51	83	254
’22	48	101	73	103	325
’21	66	89	75	122	352

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	22	76	78	87	263
’25	55	78	31	93	257
’24	46	68	65	58	236
’23	47	58	39	73	216
’22	42	91	58	89	280
’21	55	78	64	111	308

Fiscal quarters ending in the months shown.

EPS $

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	0.24	0.24	0.32	0.35	1.16
’25	0.21	0.22	0.14	(0.11)	0.46
’24	0.31	0.17	0.31	0.25	1.05
’23	0.55	0.31	0.43	0.47	1.76
’22	0.42	0.49	0.37	0.38	1.66
’21	0.21	0.29	0.28	0.09	0.87

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	23.92	32.02	33.65	38.79	77.66	68.00	51.79	61.16	46.01	43.20	Analyst estimates 2027–2029 Powerpack
	High	34.10	51.51	55.82	81.61	135.96	129.76	89.91	85.57	79.28	72.69
People
People	Employees	1,800	2,000	2,250	2,300	2,600	3,000	3,050	3,100	3,100	3,000
	Revenue/emp, $m	0.31	0.32	0.32	0.32	0.36	0.37	0.37	0.37	0.39	0.41
Income, $m
Income, $m	Revenue	563	643	714	739	931	1,106	1,137	1,159	1,220	1,215
	Gross margin, %	66.53	67.21	66.31	65.41	67.97	68.42	67.72	66.41	64.80	65.77
	EBT	112	126	112	276	148	301	339	186	98	241
	EBT margin, %	19.89	19.59	15.69	37.43	15.92	27.26	29.79	16.02	8.07	19.81
	Net income	76	126	96	229	140	263	285	168	73	182
	Depreciation	60	64	78	83	88	101	107	112	110	97
Per share, $
Per share, $	Revenue	3.77	4.29	4.72	4.83	6.01	7.05	7.23	7.35	7.74	7.79
	Earnings	0.52	0.84	0.64	1.50	0.91	1.73	1.81	1.07	0.47	1.17
	Cash flow	0.96	1.14	1.20	1.34	2.27	2.07	1.62	1.90	1.83	1.87
	Capex	(0.10)	(0.14)	(0.17)	(0.34)	(0.29)	(0.29)	(0.24)	(0.40)	(0.20)	(0.18)
	Free cash flow	0.86	1.00	1.03	1.00	1.99	1.79	1.38	1.50	1.63	1.69
	Book value	6.36	7.20	7.71	9.04	10.14	10.84	12.51	13.12	12.18	13.52
	Shares, m	149	150	151	153	155	157	157	158	158	156
Valuation, ×
Valuation, ×	P/E	60.27	44.38	82.72	44.01	124.04	49.95	44.85	67.56	111.85	60.38
	P/S	7.79	8.64	11.07	13.66	18.74	12.30	11.29	9.74	6.65	9.07
	P/B	4.62	5.15	6.78	7.30	11.10	7.99	6.52	5.46	4.22	5.23
	EV/Sales	8.12	8.88	11.55	13.77	18.86	12.30	11.43	9.90	6.81	9.03
	EV/FCF	35.56	38.23	52.79	66.29	57.03	48.52	60.09	48.59	32.36	41.66
Cash, $m
Cash, $m	Operating cash flow	144	170	182	205	352	325	254	299	288	292
	Capex	(15)	(21)	(25)	(52)	(44)	(45)	(38)	(63)	(31)	(29)
	Free cash flow	129	149	156	153	308	280	216	236	257	263
Balance, $m
Balance, $m	Working capital	213	319	311	414	358	430	493	458	432	581
	Total debt	344	339	505	357	341	256	350	319	346	200
	Net debt	186	157	339	86	110	9	146	166	184	(65)
	Shareholders’ equity	950	1,079	1,166	1,381	1,571	1,701	1,967	2,069	1,919	2,108
Returns, %
Returns, %	ROA	5.66	8.01	5.53	11.72	6.55	11.94	11.56	6.29	2.79	7.07
	ROIC	6.64	6.88	6.09	6.71	8.82	10.84	8.85	5.78	3.04	7.70
	ROE	8.32	12.44	8.56	18.01	9.51	16.63	15.56	8.33	3.68	9.03

Negative figures in brackets.

All 10 years →

Fiscal years to Jun 2026 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BBIO BridgeBio Pharma, Inc.	$13.1B	— (loss-making)	— (loss-making)	+120.39% (above 0%: growing)	n/m	+16.59% (above 0%: growing)	93.83%	(43.94%)	Compare
CORT Corcept Therapeutics Incorporated	$12.3B	212×	139×	+31.74% (above 0%: growing)	+21.21% (above 0%: growing)	−29.89% (below 0%: shrinking)	98.41%	16.12%	Compare
SMMT Summit Therapeutics PLC	$12.3B	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−112.80% (below 0%: shrinking)	0.00%	0.00%	Compare
TECH Bio-Techne Corp	$11.4B	62.0×	37.6×	+1.33% (above 0%: growing)	n/m	−6.83% (below 0%: shrinking)	65.82%	23.13%
BMRN BioMarin Pharmaceutical Inc.	$10.9B	144×	16.1×	+19.91% (above 0%: growing)	−81.60% (below 0%: shrinking)	−20.28% (below 0%: shrinking)	79.51%	11.21%	Compare
MDGL Madrigal Pharmaceuticals, Inc.	$10.6B	— (loss-making)	— (loss-making)	+71.17% (above 0%: growing)	n/m	+140.54% (above 0%: growing)	89.02%	(15.46%)	Compare
IBRX ImmunityBio, Inc.	$10.6B	— (loss-making)	— (loss-making)	+93.91% (above 0%: growing)	n/m	+13.38% (above 0%: growing)	99.42%	(120.41%)	Compare
PCVX Vaxcyte, Inc.	$10.3B	— (loss-making)	—	—	n/m	−92.55% (below 0%: shrinking)	0.00%	0.00%	Compare
KRYS Krystal Biotech, Inc.	$9.8B	38.3×	38.6×	+24.14% (above 0%: growing)	+39.10% (above 0%: growing)	+40.14% (above 0%: growing)	94.60%	49.00%	Compare
Median of peers	$10.7B	144×	38.6×	+31.74%	+21.21%	−3.45%	91.43%	0.00%

All 614 Biotechnology stocks →

Bio-Techne Corp (TECH) key facts

Strength: Net income was $181.9 million, or $1.17 per share (basic), a net margin of 15.0%.
Bio-Techne Corp (TECH) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025.
As of October 16, 2026, TECH traded at $72.54, a market capitalization of $11.4 billion.
At that price the stock trades at 62.0× trailing-twelve-month earnings and 9.3× sales; its P/E is higher than 59% of its own readings over the past ten years.
Bio-Techne Corp pays an annual dividend of $0.32 per share, a yield of 0.44%, with a payout ratio of 27.8%.
Return on equity was 9.03% and debt-to-equity 0.09.
Its Piotroski F-score is 9 out of 9 and its Altman Z-score is 15.50 (safe zone) for fiscal 2026.